在一项随机对照试验中,Roxadustat降低了血液透析患者的左心室质量指数,与rHuEPO相比,在血液透析患者中降低了左心室质量指数
Wei Tan1, Xiang Wang2, Yudong Sun3
1Department of Nephrology, The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing, China.
Journal of internal medicine
|February 12, 2024
概括
与复合人体红色素 (rHuEPO) 相比,Roxadustat治疗在血液透析患者中导致左心室缩 (LVH) 的显著回归. 这项研究表明,在这个患者群体中,roxadustat在减少LVH方面更有效.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 左心室缩 (LVH) 在血液透析 (HD) 患者中很常见,增加死亡风险.
- 罗克萨杜沙特和复合人体红色素 (rHuEPO) 是HD患者脏贫血的主要治疗方法.
- 罗沙沙斯塔特和rHuEPO对HD患者的LVH的比较作用尚不清楚.
研究的目的:
- 为了比较roxadustat与rHuEPO在降低血液透析患者左心室质量指数 (LVMI) 的疗效.
- 评估这些治疗对心脏几何和临床结果的影响.
主要方法:
- 一个多中心,前性,随机试验,在12个月内与114名HD患者进行了随机试验.
- 参与者被随机分配1:1接受roxadustat或rHuEPO,血红蛋白水平保持在10.0-12.0g/dL.
- 左心室质量指数 (LVMI) 通过心声回声计测量作为主要终点.
主要成果:
- 在roxadustat组的LVMI下降了 (116.18至110.70g/m2),但在rHuEPO组 (109.35至114.99g/m2) 增加了.
- 在两组之间观察到LVMI变化的统计学上显著差异 (p < 0.05).
- 罗沙沙斯塔特在左心室质量和终端透缩体积方面显示出潜在的益处,心血管不良事件没有显著差异.
结论:
- 罗沙杜沙特在促进血液透析患者左心室缩的回归方面表现出比rHuEPO更高的疗效.
- 这些发现表明,roxadustat是管理心脏重塑在这个人群中可能更有益的治疗选择.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.6K
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
3.6K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:11Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
640
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
640
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731